Furthermore, baricitinib, a JAK1/2 inhibitor with IFN-blocking activity, has shown benefits in several therapeutic trials (47–49); however, in a study demonstrating its effectiveness in combination with remdesivir in reducing time to recovery from COVID-19, the effect was significant among men but not women (48). Here, IFNA1 is linked to COVID-19.